Form 4: Vivos Therapeutics CFO Bradford K. Amman Acquires 15,000 Stock Options

Bradford K. Amman, CFO of Vivos Therapeutics, Inc., reports the acquisition of 15,000 stock options on June 20, 2024.

Summary

• On June 28, 2024, Bradford K. Amman, the Chief Financial Officer of Vivos Therapeutics, Inc. filed a Form 4.
• The form reports a transaction that occurred on June 20, 2024, where Amman acquired 15,000 stock options.
• The exercise price of these options is $2.38.
• One-fifth of the options vested immediately, and the remaining options will vest annually on each anniversary of the grant date through June 20, 2028.
• Following the reported transaction, Amman beneficially owns 31,667 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction. The granting of stock options can be seen as a positive sign of alignment between management and shareholders, but it's a routine event.

Positives

• The acquisition of stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

This is a standard disclosure related to executive compensation and is common in the industry.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in publicly traded companies.
• The vesting schedule of one-fifth immediately and the remainder annually over four years is a typical arrangement.
• Comparable companies in the healthcare sector also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• The granting of stock options aligns the CFO's interests with those of the shareholders, potentially incentivizing him to improve the company's performance.

Key Dates